|1.||Berneman, Zwi: 3 articles (01/2015 - 09/2006)|
|2.||Schroyens, Wilfried: 3 articles (01/2015 - 09/2006)|
|3.||Michiels, Jan Jacques: 2 articles (01/2015 - 12/2006)|
|4.||Abdusalam, Elzira: 2 articles (05/2014 - 02/2014)|
|5.||Umar, Anwar: 2 articles (05/2014 - 02/2014)|
|6.||Moore, Nicholas: 2 articles (05/2014 - 02/2014)|
|7.||Zhou, Wenting: 2 articles (05/2014 - 02/2014)|
|8.||van Vliet, Huub H D M: 2 articles (12/2006 - 09/2006)|
|9.||Chen, Kun-Zhou: 1 article (12/2015)|
|10.||Xie, Yan-Hu: 1 article (12/2015)|
06/01/1996 - "Thromboxane B2 levels were measured from blood samples obtained at pre-ischemia, and at 1 h and 48 h of reperfusion. "
08/01/1995 - "In nonrunners, however, thromboxane B2 was already elevated during ischemia (147 +/- 9%, P < .01) and remained elevated longer during recirculation (P < .05). "
01/01/1992 - "Thromboxane B2 levels were 2983 +/- 1083 pg/ml and 9483 +/- 2218 pg/ml at pre-ischemia and at one hour of reperfusion respectively (p less than 0.04). "
03/01/1991 - "Both thromboxane B2 and 6-keto-prostaglandin F1 alpha increased significantly during ischemia compared with preischemic values in all groups of hearts. "
01/01/1991 - "Blood samples were drawn from the renal vein before ischemia and after reperfusion to determine serum levels of thromboxane B2 (TxB2). "
03/01/1994 - "Relationship between thromboxane B2 and 6-keto-prostaglandin F1 alpha in sepsis."
04/01/1993 - "On the other hand, pulmonary lavage immunoreactive thromboxane B2 (iTXB2) levels were increased both four and 18 hours after the initiation of sepsis. "
01/01/1988 - "During sepsis, urinary thromboxane B2 excretion continued at presepsis values in all groups. "
05/01/1986 - "The elevation in thromboxane B2 occurring with GBS sepsis did not occur in the DAZ-pretreated animals.(ABSTRACT TRUNCATED AT 250 WORDS)"
10/01/1991 - "Imbalance between plasma levels of thromboxane B2 and 6-keto-prostaglandin F1 alpha during subacute endotoxin-induced hyperdynamic sepsis or multiple organ failure syndrome in sheep."
|3.||Pulmonary Hypertension (Ayerza Syndrome)
07/01/1993 - "The mutant caused significantly greater pulmonary hypertension and arterial plasma thromboxane B2 levels than the large capsule strain. "
09/01/2000 - "The induction of pulmonary hypertension decreased the platelet count and increased the plasma levels of thromboxane B2 and 6-keto-prostaglandin F1alpha. "
02/01/1998 - "In patients with pulmonary hypertension, the plasma concentration of thromboxane B2 and the ratio of thromboxane B2 to 6-keto-prostaglandin F1 alpha were greater than in healthy controls: 210 +/- 49 versus 28 +/- 4 pg/mL (P < 0.05) and 32.6 +/- 8.9 versus 5.7 +/- 1.8 (P < 0.01), respectively. "
03/01/1993 - "PAF, infused at hourly intervals from 0-4 h, caused increases in plasma concentrations of thromboxane B2 (TxB2) concomitant with pulmonary hypertension and vasoconstriction in anesthetized pigs. "
04/01/1991 - "Thromboxane B2 may be a mediator of neonatal persistent pulmonary hypertension. "
|4.||Asthma (Bronchial Asthma)
11/01/1990 - "[Contents of 6-keto-prostaglandin F1 alpha and thromboxane B2 in the blood of patients with bronchial asthma]."
08/01/1990 - "[Changes in plasma thromboxane B2 and 6-keto-prostaglandin F1 alpha in bronchial asthma]."
06/01/2000 - "Plasma concentration of thromboxane B2(TXB2) and 11-dehydro-TXB2(11-DH-TXB2) and P-selectin (CD 62P) on platelet surface were measured in 44 patients with asthma and in 18 normal individuals using ELISA and FCP. "
09/01/2000 - "The changes on symptoms and signs of asthma, pulmonary function, T-lymphocyte subsets, plasma soluble interleukin-2 receptor (sIL-2R), thromboxane B2(TXB2) and 6-keto-prostaglandin F1 alpha(6-keto-PGF1 alpha) were observed before and after treatment. "
11/01/1999 - "Time-course study of the levels of urinary leukotriene E4, serum thromboxane B2 and serum eosinophil cationic protein in spontaneous asthma attacks in five children."
|5.||Peripheral Vascular Diseases (Peripheral Vascular Disease)
07/01/1989 - "1. Aggregation of diluted whole blood (impedance method) and thromboxane B2 production during aggregation were measured in cigarette smokers and non-smokers, aged 41-68 years, with (n = 14) and without (n = 15) major symptomatic peripheral vascular disease. "
06/30/1989 - "Similar amounts of TxA2 (measured as thromboxane B2, TxB2) were generated at the site of plug formation in the patients with peripheral vascular disease (PVD) and in the control subjects. "
02/01/1986 - "Platelet half-life, plasma thromboxane B2 and circulating endothelial-cells in peripheral vascular disease."
05/01/1997 - "In 27 healthy adults, 51 patients with clinically manifested coronary heart disease as well as in 31 patients with peripheral vascular disease parallel samples drawn in the presence of chloroquine showed lower thromboxane B2 in all these three groups of patients, especially in conditions associated with platelet activation and high thromboxane B2-values. "
05/01/1987 - "We studied the effect of nafazatrom on plasma prostacyclin (PGI2) levels, platelet function, and thromboxane B2 (TxB2), and 12-hydroxy-eicosatetraenoic acid (12-HETE) production and clinical improvement in 12 patients with peripheral vascular disease (PVD) by means of a double-blind crossover trial of placebo, 800 or 1600 mg of nafazatrom four times daily for 1 week, with intervening 2-week washout periods. "
|1.||6-Ketoprostaglandin F1 alpha (6 Ketoprostaglandin F1 alpha)
|2.||Aspirin (Acetylsalicylic Acid)
|5.||Thromboxane A2 (A2, Thromboxane)
|8.||Histamine (Histamine Dihydrochloride)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||Oral Surgery (Maxillofacial Surgery)